Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892027) titled 'Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy' on Oct. 17.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).
Primary Sponsor: University of Michigan Rogel Cancer Center
Condition:
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Intervention:
Biological: Axicabtagene Ciloleucel
Procedure: B...